Clinical data | |
---|---|
Other names | CVL-751; PF-6649751; PF-06649751 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H16F3N3O3 |
Molar mass | 391.350 g·mol−1 |
3D model ( JSmol) | |
| |
|
Tavapadon (developmental code names CVL-751, PF-06649751) is a dopamine receptor agonist for the treatment of Parkinson's disease. [1] [2] [3], under development by Cerevel Therapeutics who acquired Tavapadon from Pfizer in 2018. It acts as a selective partial agonist of the dopamine D1 (Ki = 8.54 nM) and D5 receptors. [2] [3] It also shows biased agonism for Gs-coupled signaling. [2] As of July 2021, tavapadon is in phase 3 clinical trials for Parkinson's disease. [1]